JP2024510215A5 - - Google Patents

Info

Publication number
JP2024510215A5
JP2024510215A5 JP2023555565A JP2023555565A JP2024510215A5 JP 2024510215 A5 JP2024510215 A5 JP 2024510215A5 JP 2023555565 A JP2023555565 A JP 2023555565A JP 2023555565 A JP2023555565 A JP 2023555565A JP 2024510215 A5 JP2024510215 A5 JP 2024510215A5
Authority
JP
Japan
Prior art keywords
protein
item
target
approximately
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/019984 external-priority patent/WO2022192694A1/en
Publication of JP2024510215A publication Critical patent/JP2024510215A/ja
Publication of JP2024510215A5 publication Critical patent/JP2024510215A5/ja
Pending legal-status Critical Current

Links

JP2023555565A 2021-03-12 2022-03-11 タンパク質発現のための系及び方法 Pending JP2024510215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160672P 2021-03-12 2021-03-12
US63/160,672 2021-03-12
PCT/US2022/019984 WO2022192694A1 (en) 2021-03-12 2022-03-11 Systems and methods for protein expression

Publications (2)

Publication Number Publication Date
JP2024510215A JP2024510215A (ja) 2024-03-06
JP2024510215A5 true JP2024510215A5 (enExample) 2025-03-19

Family

ID=83228345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555565A Pending JP2024510215A (ja) 2021-03-12 2022-03-11 タンパク質発現のための系及び方法

Country Status (11)

Country Link
US (1) US20240141373A1 (enExample)
EP (1) EP4305176A4 (enExample)
JP (1) JP2024510215A (enExample)
KR (1) KR20230169989A (enExample)
CN (1) CN117321209A (enExample)
AU (1) AU2022235284A1 (enExample)
BR (1) BR112023018404A2 (enExample)
CA (1) CA3211755A1 (enExample)
IL (1) IL305817A (enExample)
MX (1) MX2023010658A (enExample)
WO (1) WO2022192694A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022002956A (es) * 2019-09-16 2022-05-13 Excepgen Inc Sistemas y métodos para expresión de proteínas.
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741022B2 (en) * 2006-01-18 2010-06-22 Wisconsin Alumi Research Foundation Protein inhibitor of Ran activity and methods of use thereof
CN102391358B (zh) * 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
DE602007008870D1 (de) * 2006-04-24 2010-10-14 Amc Amsterdam Verbessertes verfahren zur behandlung von cystischer fibrose
ES2923757T3 (es) * 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
US12590321B2 (en) * 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
FR3081169B1 (fr) * 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
US20220195462A1 (en) * 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
MX2022002956A (es) * 2019-09-16 2022-05-13 Excepgen Inc Sistemas y métodos para expresión de proteínas.

Similar Documents

Publication Publication Date Title
JP2021533753A5 (enExample)
Robinson Growth factors: therapeutic advances in wound healing
KR102589415B1 (ko) 락테이트 축적을 방지하면서 세포 배양물을 증식하는 방법 및 시스템
US20200115442A1 (en) Protein aqueous suspension preparation
AU2009223115B2 (en) Recombinant production of authentic human proteins using human cell expression systems
AU2021206008A1 (en) Engineered Leishmania cells
RU2014137109A (ru) Нуклеиновая кислота, содержащая или кодирующая структуру "стебель-петля" гистонов и последовательность поли(а) или сигнал полиаденилирования, для повышения экспрессии кодируемого терапевтического белка
JP2020530273A5 (enExample)
KR19980064289A (ko) 약리학적으로 통제가능한 자가 증진 발현 시스템
KR20080017362A (ko) 창상 치유를 위한 ｖｅｇｆ의 용도
KR102593407B1 (ko) 개선된 발효 공정
Carton et al. Protein therapeutics (introduction to biopharmaceuticals)
Talaverón et al. Neural progenitor cell implants modulate vascular endothelial growth factor and brain-derived neurotrophic factor expression in rat axotomized neurons
EP4305176A1 (en) Systems and methods for protein expression
US20040053368A1 (en) Collagen-binding hybrid polypeptide
EP3921422B1 (en) Chloride-inducible prokaryotic expression system
US11034721B2 (en) Method for the reduction of viral titer in pharmaceuticals
WO2022192687A1 (en) Synthetic promoters for gene therapy and protein expression
EP3752592B1 (en) Buffer formulation method and system
CN1034588C (zh) 人促生长因子c的改进生产方法
JP2002060400A (ja) コラーゲン結合活性および血管新生調節活性を有するハイブリッドポリペプチド
Nazemi Zadeh et al. Lab-scale Production of Recombinant Platelet-derived Growth Factor-BB Homodimer (PDGF-BB) in Microbial Expression System
RU2021105649A (ru) Молекулы нуклеиновой кислоты и пути их применения для невирусной генной терапии
CN118574931A (zh) 一种新型5’-非翻译区元件及其应用
US20230112648A1 (en) Non-naturally occurring polyadenylation elements and methods of use thereof